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Osteocytes, which represent up to 95% of adult skeletal cells, are deeply embedded
in bone. These cells exhibit important interactive abilities with other bone cells such
as osteoblasts and osteoclasts to control skeletal formation and resorption. Beyond
this local role, osteocytes can also influence the function of distant organs due to the
presence of their sophisticated lacunocanalicular system, which connects osteocyte
dendrites directly to the vasculature. Through these networks, osteocytes sense changes
in circulating metabolites and respond by producing endocrine factors to control
homeostasis. One critical function of osteocytes is to respond to increased blood
phosphate and 1,25(OH)2 vitamin D (1,25D) by producing fibroblast growth factor-23
(FGF23). FGF23 acts on the kidneys through partner fibroblast growth factor receptors
(FGFRs) and the co-receptor Klotho to promote phosphaturia via a downregulation of
phosphate transporters, as well as the control of vitamin D metabolizing enzymes to
reduce blood 1,25D. In the first part of this review, we will explore the signals involved in
the positive and negative regulation of FGF23 in osteocytes. In the second portion, we
will bridge bone responses with the review of current knowledge on FGF23 endocrine
functions in the kidneys.
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INTRODUCTION
The mammalian skeleton is formed by several types of bone which interconnect to provide
structural support for the body. In adult humans, the reference value for the skeleton weight
is 10.5 kg (1, 2) representing up to 15% of the average body weight. Bone mass is dynamically
regulated during a lifetime, and subjected to changes with uncontrollable parameters such as age,
gender, genetics, and ethnicity; as well as controllable factors such as lifestyle behaviors including
physical activity levels, smoking and alcohol consumption patterns, and diet (3, 4). Beyond its
important role to enable mobility and provide needed support and structure to the body, bone
represents an important reservoir of several minerals including phosphate and calcium, both of
which are required for proper mineral metabolism and cellular functions (5).
Bone is a mineralized connective tissue formed with three primary cell types that direct intrinsic
skeletal properties: osteoclasts, which resorb mineralized bone; osteoblasts, which form the bone
matrix; and osteocytes, which are considered terminally differentiated osteoblasts (6, 7). Although
morphologically and functionally distinct in the bone, osteoclasts, osteoblasts, and osteocytes are
interdependent and produce growth factors to support each other’s functions as well as responding
in a coordinated manner to metabolic demands, physical stimuli, and structural duties (8). The
three main bone cells are derived from two distinct lineages; osteoblasts and osteocytes derive from
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pluripotent mesenchymal stem cells and share the same
progenitors as fibroblasts and adipocytes (9, 10), whereas
osteoclasts are derived from hematopoietic progenitors in the
monocyte and macrophage lineage (11–13).
The osteocytes, which represent the majority of adult skeletal
cells, are deeply embedded with abilities to communicate locally
with osteoblasts and osteoclasts. This function is necessary to
control skeletal formation as orchestrated by osteoblasts, and
bone resorption dictated by osteoclasts, as well as controlling
the physiological function of distant organs such as the kidney.
Taking advantage of its dendrites, which connect to the
vasculature and give these atypical cells direct access to the
circulation, the osteocyte can send and receive signals with the
vascularized organs. Among the important osteocyte-secreted
factors is fibroblast growth factor-23 (FGF23). Once produced
and secreted by osteocytes, this hormone preferentially acts on
kidney and parathyroid glands to regulate phosphate and vitamin
D homeostasis. FGF23 activity mainly occurs through the
binding of FGF23 to FGF receptor (likely FGFR1), which requires
the presence of its membrane and/or soluble co-receptor Klotho
for a potent FGF23-induced downstream signaling cascade
(14). In this review, the stimulative and repressive regulatory
mechanisms involved in FGF23 production and processing in
osteocytes will be discussed. We will also bridge the control of
FGF23 in osteocytes with highlighting the key signaling pathways
involved in phosphate, 1,25D, calcium, and sodium metabolism
induced by FGF23 in the kidneys.
THE OSTEOCYTE: A CRITICAL BONE AND
ENDOCRINE CELL
As the most prevalent cell in bone, osteocytes have important
roles both within, and outside the skeleton. The osteocytes
are considered as major orchestrators of skeletal activity; these
cells can sense and integrate mechanical and chemical stimuli
from the microenvironment with the goal to properly regulate
bone formation and resorption. Osteocytes derive from mature
and matrix-producing terminally differentiated osteoblasts (6).
During their last phase of differentiation, mature osteoblasts
become embedded in the matrix and generate cellular extensions,
which are future osteocyte dendrites. To establish a sophisticated
and complex network called the lacunocanalicular system, the
dendrites of the newly formed osteocytes are fastened with the
dendrites of existing osteocytes through a multitude of canaliculi
(15). Even after the terminal differentiation of mature osteoblasts
to generate osteocytes, the latter remain active in contributing
to bone remodeling. For instance, osteocytes produce sclerostin
(SOST), which binds to low-density lipoprotein receptor-related
protein (Lrp)5/6, and neutralizes the anabolic Wnt/beta-catenin
pathway (16, 17), thus negatively regulating bone formation.
Osteocytes also produce the receptor activator of nuclear factor-
κB ligand (RANKL) which stimulates osteoclastogenesis, thus
promoting bone resorption (18, 19).
In bone, osteocytes are bathed in canalicular fluid that
delivers and exchanges nutrients, circulating factors, mechanical
signals, and oxygen between the circulation and the “fixed and
embedded” osteocytes (20). During the last decade, the osteocyte
lacunocanalicular network has gained tremendous attention
because of accumulating and convincing evidence describing
osteocytes as amajor endocrine cell, and its role in the production
of critical hormones targeting several organs. One of the most
important osteocyte-secreted factors is FGF23. This hormone
was first characterized as a mammalian “phosphatonin” by
identifying stabilizing mutations in the FGF23 gene in patients
with autosomal dominant hypophosphatemic rickets (ADHR), a
renal phosphate wasting disorder (21).
FGF23 PRODUCTION AND CLEAVAGE IN
OSTEOCYTES
FGF23 is a phosphaturic hormone derived and secreted primarily
by bone osteocytes. Mature, bioactive FGF23 is physiologically
designed to target the kidney to regulate phosphate and vitamin
D homeostasis; and, in a feedback mechanism to control bone
mineralization and FGF23 production (22, 23). The mechanisms
of FGF23 regulation in osteocytes are not fully understood.
Several breakthroughs have been made that greatly improved our
knowledge on the mechanisms of osteocytic FGF23 upregulation
or downregulation through differential signaling pathways, as
well as the pathophysiological response to multiple stimuli. In
addition to several mechanisms involved in the transcriptional
regulation of FGF23, another layer of FGF23 regulation in bone
is the ability of the mature protein to be proteolytically cleaved
within osteocytes to generate inactive FGF23 fragments before its
secretion into the bloodstream (24).
Regulation of Osteocytic FGF23 by
Phosphate, FGF23, FGFR Activation, and
Klotho
Circulating levels of phosphate control FGF23 production
in mammals (25, 26). Although the mechanisms of FGF23
regulation by phosphate are not fully understood, recent studies
have implicated the type III sodium phosphate co-transporter
PiT2 (Slc20a2) as being required for mediating phosphate-
dependent FGF23 production (27). Indeed, in vivo studies using
dietary protocols in PiT2 knock out mice showed that the
deletion of PiT2 results in “inappropriately” normal intact,
bioactive FGF23 in the circulation in response to high or low
phosphate diet, which should normally increase or decrease
FGF23, respectively (27). Using an ex vivo system of cultured long
bone shafts, parallel studies showed that the PiT2 KO bone shafts
failed to undergo Pi-induced FGF23 production, illustrating that
PiT2 could be required for FGF23 induction in mouse bone (27).
These new findings provided interesting insight underlying the
phosphate-dependent regulation of FGF23 secretion, perhaps via
PiT2 regulating phosphate uptake in osteocytes (27) (Figure 1).
In another study, using proteomic analysis to identify
potential upstream sensors in response to elevated phosphate
through dietary intervention, the FGFR1 isoform FGFR1c was
shown to be activated through the phosphorylation of FGFR
substrate 2α (FRS2α, on tyrosine 196) under high phosphate
conditions, but in the absence of an FGF ligand. These
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FIGURE 1 | FGF23 regulation in osteocytes. In osteocytes, FGF23 is positively regulated by different factors and pathways (shown in green). In presence of high
phosphate, the receptor FGFR1 may sense this condition and the adaptor FRS2α is phosphorylated thus activating FGFR1 and the MEK/pERK/EGR1 pathway
leading to FGF23 transcription. It is also possible that the transporter PiT2 senses phosphate increases in osteocyte and responds by inducing FGF23. The activation
of FGFR1 by other FGFs such as FGF2 may induce Pi3K/AKT/pERK/EGR1 leading to FGF23 upregulation. The activation of PTH1R by PTH induces cAMP/PKA and
the transcription factor NURR1 leading to FGF23 induction. Inflammatory conditions are potent FGF23 inducers; lipopolysaccharide (LPS) may bind to osteocyte toll
like receptor 4 (TLR4) and induce MyD88/IRAK/TRAF6/NF-κB to trigger FGF23 transcription (or may act through anemia/hypoxia). The binding of IL-6 to IL-6R in
osteocytes may induce JAK/STAT3 and subsequent FGF23 expression. The cytokines IL-1β and TNF-α can induce NF-κB in osteocytes leading to FGF23
transcription. In the condition of iron deficiency, HIF protein is stabilized, an important mechanism involved in FGF23 upregulation. The active form of vitamin D
(1,25-dihydroxyvitamin D; 1,25D), which results from the conversion of 25-hydroxyvitamin D (25D) inside or outside the osteocyte, could promote the formation of the
complex 1,25D-VDR-RXR which binds the vitamin D receptor element (VDRE, not shown here) and induces FGF23 transcription. The signaling through the
TGF-β-Activin Receptors ALK4/5/7 promotes calcium entry in cell through Orai1 and this process activates calcineurin and NFAT and their binding, which induces
FGF23. Lithium-induced increased intracellular calcium could also increase FGF23 in osteocytes through calcineurin and NFAT activity. An activation of a yet unknown
GPRC could trigger FGF23 transcription through XLαs or Gq/11α and inositol 1,4,5-trisphosphate (IP3) which may activate PKC and stimulate the MAPK pathway.
FGF23 can be negatively regulated by other elements and pathways (shown in red). For instance, insulin can bind to IGFR1 and induce PI3K/AKT/FOXO1 pathway
which represses FGF23. Phex and Dmp1 activities in osteocytes may control FGFR1/PI3KR1/GRB and cell differentiation to restrain FGF23 production. Dmp1 activity
may also neutralize the FAK/MAPK pathway restricting FGF23 expression.
studies were consistent with the idea that phosphate-sensing
mechanisms could control FGF23 production in osteocytes
through ligand-independent FGFR1 activation (28, 29). These
data suggested that high Pi diet-induced serum FGF23 increases
in mice may be mediated by the phosphorylation of FGFR1,
a potential “phosphate receptor” upstream of FGF23, which
induced the mitogen activated protein kinase (MAPK) and
extracellular signal-regulated kinase (ERK) pathways to control
FGF23 synthesis (28). Structural and crystallographic studiesmay
be required to understand how an ion can activate an FGFR, as
well as whether PiT2 is involved in this regulation (Figure 1).
Additionally, in vivo studies have reported that conditional
deletion of FGFR1 specifically from the osteocytes of Hyp
mice, a mouse model of X-linked hypophosphatemia (XLH)
that exhibits elevated FGF23 production, improves the rickets
and osteomalacia phenotype of these mice in association
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with a decrease in both FGF23 bone mRNA and circulating
protein. These mice also undergo an alleviation of their
hypophosphatemic status, as well as an increase of plasma
1,25D levels (30). Furthermore, promoter studies identified that
the activation of FGFR1 signaling through FGF2 is dependent
on the PI3K-AKT pathway in the MC3T3-E1 osteoblastic cell
line, providing evidence that Fgf23 gene promoter activity
is induced by FGFR1 activation (30). In addition to genetic
interventions, pharmacologic-based studies have shown that
activation of FGFR1 induces FGF23 production and leads to
hypophosphatemia, whereas the inhibition of FGFR signaling
attenuates FGF23 production (31) (Figure 1).
Another study by Hori et al. investigated whether phosphate
could induce reactive oxygen species (ROS) in vitro, leading
to increased FGF23 expression. Using the osteoblastic cell line
UMR-106, these investigators showed that elevated phosphate
in the culture media enhances the production of ROS, and that
hydrogen peroxide further boosts FGF23 production in a dose-
dependent manner, an effect which can be neutralized by an
inhibitor of NADPH oxidase (32). These discoveries suggested
that in vitro phosphate directly enhanced FGF23 transcription
by stimulating NADPH-induced ROS production and the MEK-
ERK pathway. How this translates to the signaling in the
osteocyte in vivo will be an interesting facet to this potential
regulatory network.
Circulating FGF23 ismarkedly elevated during chronic kidney
disease (CKD), and this is associated with poor long-term
outcomes. By investigating the regulation of FGF23 through
FGFR1, Hassan et al. demonstrated that the activation of FGFR1
is essential for the high levels of FGF23 observed during both
acute and chronic uremia in mice and rats (33). In addition,
in mice treated with the receptor FGFR1 inhibitor PD173074
by oral gavage followed with an acute kidney injury induction
using folic acid, the prevailing increased FGF23 was reduced
by 50% in calvaria and led to a complete prevention of the
circulating intact FGF23 rises (33). In a more prolonged uremic
condition using a diet with adenine plus high-phosphorus for
14 days to induce CKD, which resulted in high levels of Fgf23
mRNA and serum FGF23 in rats, an oral gavage intervention
with PD173074 given during the last 2 days of treatment
reduced FGF23 induction by 75% in calvaria and completely
normalized circulating FGF23 (33). Therefore, the FGFRs may
play an important role in osteocyte-bloodstream communication
to control FGF23 production.
Asmentioned above, FGF23 signals via the interaction with its
receptor FGFR1c and its specific co-receptor Klotho (14, 34). A
recent investigation has shown that Klotho could be detected in
osteocytes (35) suggesting that FGF23 may be one of the ligands
that activates FGFR1 in osteocytes, thereby regulating the FGF23
gene transcription in a positive feedback loop. The expression of
Klotho in osteocytes has been suggested to contribute to bone
formation and bone volume increases coupled with enhanced
osteoblast activity (35). Although Klotho has been detected in
bone (35), the kidney, parathyroid glands and brain remain
the primary organs with abundant expression of Klotho to
the best of our current knowledge (36–38). However, it is
possible that in response to pathological circumstances, bone cells
could enhance Klotho expression, thus modulating bone FGFR1
signaling via FGF23.
Through proteolytic cleavage of the membrane-bound klotho
(mKL) (39–42), a soluble form of Klotho (sKL) can be liberated
into the circulation (43, 44). Soluble Klotho has been described
to have a direct role to regulate Wnt and MAPK pathways in
osteoblastic UMR-106 cells in concert with the presence of FGF23
(45). Indeed, in vitro studies showed that a co-treatment of
UMR-106 cells with FGF23 and soluble Klotho activated MAPK
signaling, leading to an increase of Dickkopf-1 (DKK1) protein,
a soluble inhibitor of Wnt/beta-catenin signaling (45). The
induction of Dkk1 through FGF23/FGFR/sKL was shown to be
dependent upon the MAPK pathway since the inhibition of this
pathway using theMEK inhibitor U0126 completely abrogated p-
ERK/ERK induction and abolished downstreamDkk1 expression
(45). The binding of the secreted Dkk1 to the receptors Frizzled
(Fz) and Lrp5/6 thus promoted the phosphorylation of β-catenin
and inactivated the Wnt pathway in osteoblasts (45). Other
studies have shown that a treatment of UMR-106 cells with
soluble Klotho and FGF23 dose-dependently increased MAPK
and Egr1 mRNA responses, an effect which was FGFR- and
MEK-dependent, and led to FGF23 upregulation (46). Future
studies are needed to confirm potential expression of Klotho
in osteocytes and under some circumstances whether FGF23
binding to FGFR1-Klotho complex in osteocytes could induce
FGF23 expression.
Signals Involved in the Positive Regulation
of FGF23 by Inflammation and Iron
Inflammation is a complex phenomenon involving multiple
immune and non-immune cells which cooperate to respond
to endogenous and exogenous events by secreting specific
pro-inflammatory and/or anti-inflammatory factors. Pro-
inflammatory stimuli such as the cytokines tumor necrosis factor
alpha (TNFα), interleukin 1β (IL-1β), the tumor necrosis factor-
like weak inducer of apoptosis (TWEAK), and the bacterial
component lipopolysaccharide (LPS) have all been shown to
dose-dependently upregulate FGF23 in the osteocyte-like cell
line IDG-SW3 (47). Particularly, TNF and IL-1β induce FGF23
expression via nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-κB) (47), a major transcription factor
complex involved in the control of cytokines and in the
mediation of multiple pro-inflammatory cellular responses.
The serine/threonine kinase p38 mitogen-activated protein
kinase (p38MAPK), which is activated by several cellular stress
stimuli and involved in the transcriptional activity of NF-κB, is
another positive regulator of FGF23 in bone cells (48). Other
investigations have shown that the serine/threonine kinase
protein kinase C (PKC), which drives FGF23 expression in
response to phorbol ester 12-O-tetradecanoylphorbol-13-acetate
(PMA), can be suppressed by 75% in the presence of the PKCα/β
inhibitor Go6976. These studies suggested that PKC is a positive
regulator of FGF23 synthesis in IDG-SW3 osteocytic cells
via NF-κB (49). Furthermore, Notch signaling, which can be
mediated by pro-inflammatory cytokines such as TNF-α (50),
has been described by Tamamura et al., to positively regulate
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FGF23 expression which colocalizes with Notch signaling
downstream targets, Notch, and Hes1 in mouse osteocytes
and UMR-106 osteoblastic cells (51). A study also identified
a potential new pathway mediated by G protein–IP3/PKC
events to control FGF23 production (52). It was shown that
the ablation of the extra-large Gα subunit (XLαs) or Gq/11α in
osteocyte-like Ocy454 cells activated IP3/PKC and stimulated
the MAPK/ERK1/2 pathway leading to FGF23 induction (52).
It is assumed that the trigger of the IP3/PKC/MAPK pathway is
controlled by a G protein-coupled receptor which remains to be
identified (Figure 1).
More recently, the use of CRISPR/Cas9 technology has helped
to identify control regions for the Fgf23 gene in response to
various inflammatory stimuli in mice. An enhancer site − 16kb
from the transcription start site of the murine Fgf23 gene
was deleted via CRISPR, and this study demonstrated that
FGF23 expression in bone, bone marrow, spleen, liver, thymus,
and intestine was attenuated in response to LPS injection.
This deletion was also associated with decreased intact FGF23
compared to normal mice treated with LPS. Similar effects were
observed in response to direct TNF-α and IL-1β injections,
highlighting the importance of this genomic region in mediating
inflammation-induced FGF23 expression (53). Further studies
showed that an additional proximal enhancer region in Fgf23
mediates LPS-induced FGF23 expression in vivo through binding
motifs to several known transcription factors that mediate
inflammation, including NF-κB (54).
Persistent iron deficiency in mice has been shown to
induce a pro-inflammatory state (55) that induces a heightened
inflammatory response to stimuli such as LPS (55, 56). Both iron
deficiency and inflammation increase FGF23 transcription by
activating among other signaling pathways, Hif1α, and associated
MAPK signaling, in osteocytes (57, 58). Wild type mice fed
an iron deficient diet for 8 and 12 weeks showed 5- and 10-
fold increases of Fgf23 transcripts, respectively, in femur/tibia
samples (57). In vitro, treatment of UMR-106 cells with the
iron chelator, deferoxamine (DFO) resulted in marked increases
in Fgf23 mRNA, partially dependent on MAPK activity in
association with Hif1α stabilization (57, 58) (Figure 1). These
discoveries suggest that absolute iron deficiency, characterized
by a depletion of both iron stores and circulating iron, promotes
FGF23 transcription through Hif1α. Similarly, a functional iron
deficiency via a treatment of mice with hepcidin also increased
bone Fgf23 mRNA expression (58).
The cytokine IL-6, a known marker of inflammatory states
has also been shown to contribute to FGF23 production. In a
mouse model of folic acid–induced acute kidney injury, bone
Fgf23 mRNA expression increased together with serum FGF23
as well as several circulating cytokines including IL-6 (33). When
fed with an adenine diet to induce CKD, IL-6 knock-out mice
failed to increase bone Fgf23 mRNA, resulting in an attenuation
of circulating FGF23 levels in comparison to wild-type mice with
CKD; these data suggest a direct contribution of IL-6 to the
increased FGF23 observed during CKD (59). Further, ex vivo and
in vitro studies have shown that a treatment of calvaria organ
cultures and UMR-106 cells with the IL-6/soluble IL-6 receptor
fusion protein induced STAT3 phosphorylation, and increased
Fgf23 promoter activity, suggesting a direct effect of IL-6 on the
positive regulation of FGF23 expression (59).
Hypoxia and Erythropoietin as Positive
Regulators of FGF23
Hypoxia inducible factors (HIFs) are constitutively expressed
transcription factors that are critical for sensing oxygen and iron
levels in the body. Oxygen and iron are important co-factors
for the function of HIF-prolyl hydroxylase domain enzymes
(HIF-PHDs), which help maintain the constant turnover of
HIFs by marking them for degradation. As stated above, it
was shown that iron deficiency can drive FGF23 expression
in a mouse model of autosomal dominant hypophosphatemic
rickets (ADHR) (57). Wild type and ADHR mice (harboring
the FGF23-R176Q stabilizing ADHR mutation) fed an iron-
deficient diet had elevations in “total” serum FGF23 (intact
bioactive FGF23 + proteolytic fragments), however only iron-
deficient ADHR mice had increases in intact FGF23 due to
their inability to cleave and inactivate the bioactive form of
FGF23. This and subsequent studies helped tie together iron
handling and phosphate homeostasis, a link that can likely be
explained through HIF activity. An iron-deficient state leads to
HIF stabilization due to the lack of iron as a co-factor for the
HIF-PHDs to tag HIF for degradation. In vitro studies have
shown HIF-mediated induction of FGF23 mRNA expression in
two different osteoblast cell lines, as well as evidence of HIF
binding to the FGF23 promoter (60).More recently, a prospective
study in ADHR patients that co-presented with an iron deficiency
phenotype demonstrated that iron repletion in these patients
reduced their circulating levels of FGF23 and normalized serum
phosphate levels. Thus, providing oral iron is a novel therapeutic
approach to this disease (61). This finding was supported by
studies in iron-deficient women showing that rescue of iron
deficiency using iron dextran lowered the prevailing elevated
FGF23 (62). It is important to note the type of intravenous iron
used, as it has been well-documented that certain types of iron
formulations, especially those with carboxymaltose backbones
can cause hypophosphatemia due to elevating intact FGF23
(63), potentially through altering FGF23 intracellular proteolysis
(see below).
Erythropoietin (EPO) is a hormone made in the kidney that
induces new red blood cell production in the bone marrow in
response to anemia or blood loss. Recombinant human EPO
(rhEPO) is currently used as a therapy to treat anemia related
to CKD. Recently, several studies revealed that this hormone
can induce FGF23 expression (64–66). WT mice given acute
rhEPO treatment after 6 h or after 3–4 days of consecutive
injections resulted in elevated total and intact FGF23 and
bone marrow Fgf23 mRNA expression (64). To understand the
effects of chronically elevated EPO, reports using the transgenic
Tg6 mouse model of EPO overexpression showed that these
mice have basal elevations in total and intact FGF23 (65, 67).
Chronic overexpression of EPO can lead to iron deficiency, so to
determine whether the iron deficiency was causing the elevated
FGF23, mice were given iron dextran. This only modestly
decreased intact FGF23, showing that EPO was primarily driving
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FGF23 expression (65). In healthy human subjects, total FGF23
was elevated 24 h after a single rhEPO dose with no changes
in intact FGF23 (66). In another study, a small population of
anemic patients with normal kidney function were given a single
dose of rhEPO. This increased total and intact FGF23 over the
span of 12–18 h after the injection (64). Few in vivo studies
have examined the effect of curing anemia of CKD on mineral
metabolism. Most recently, a single rhEPO injection in CKD
mice did increase total serum FGF23 after 6 and 24 h but had no
effect on intact FGF23 (65).
To mitigate potential adverse effects of high rhEPO treatment,
new strategies are leveraging the HIF system by creating
inhibitors of the HIF prolyl hydroxylases (HIF-PHDs) called
HIF-PHDs inhibitors (HIF-PHI). These therapeutics have
become increasingly important for anemic patients with CKD,
where they promote endogenous EPO production by stabilizing
HIFs. This class of drug also reduce hepcidin levels to increase
iron utilization in tissues thereby creating a synergistic effect
in providing iron availability to newly forming red blood cells
(68). Recent studies have shown in normal mice that several
HIF-PHIs can regulate Fgf23 expression. For instance, FG-4592
(Roxadustat) was shown to increase bone Fgf23 mRNA and
circulating intact FGF23 (58, 66). Elevations in total and intact
FGF23 were observed in WT mice treated with the HIF-PHI
BAY 85-3934 (Molidustat) after 6 h that returned to baseline by
24 h. This study showed that elevated EPO precedes increases in
FGF23 in response to HIF-PHI BAY85-3934, suggesting that the
cause for elevated FGF23 in response to this treatment was due
to elevated EPO. This was confirmed by treating HIF-PHI mice
with an EPO-neutralizing antibody, which completely attenuated
the increased serum total FGF23 (69). A recent paper, however,
showed that EPO and HIF-PHI treatment of anemic mice with
CKD resulted in suppressed FGF23. This study suggested that
under conditions of anemia, as opposed to mice with normal
iron homeostasis, rescuing iron utilization during CKD may be
a more potent suppressor of FGF23 than EPO and HIF-PHIs
are stimulators (70). Although EPO and HIF-PHI can induce
FGF23, further studies are required to delineate the mechanisms
directing these components on osteocytic FGF23 production.
Signals Involved in the Transcriptional
Regulation of FGF23 by PTH
Parathyroid hormone (PTH) is a hormone secreted by the
parathyroid glands that regulates calcium utilization through
its effects on bone, kidney, and intestine (71–73). During
CKD, a secondary hyperparathyroidism occurs in which
PTH is excessively secreted, in response to factors such as
hyperphosphatemia, hypocalcemia, and low 1,25D levels, to
potentially promote elevated FGF23 (74). Using bioinformatics
and chromatin immunoprecipitation assays, studies have
reported that Nurr1 is an essential transcription factor involved
in FGF23 upregulation in response to PTH in UMR-106 cells.
Furthermore, in a mouse model of CKD, the administration of
a calcimimetic, which is known to activate the calcium-sensing
receptor in different tissues (75) with the goal to attenuate PTH
levels and actions, reduced FGF23 concentrations as well as bone
Nurr1 mRNA and protein levels (76). To test the relationships
between PTH and FGF23, a mouse model with constitutive
activation of PTH receptor (PTHR) signaling in osteocytes was
used by Rhee et al. in a report that showed that PTHR activation
increased FGF23 expression in vivo and in vitro through cAMP
and Wnt-dependent mechanisms (77). In addition, Knab et al.
showed that PTH-induced increases in FGF23 expression were
PKA-dependent in osteocyte-like cells, suggesting that FGF23
production is regulated by the cAMP/PKA/Nurr1 pathway in
response to PTH (78) (Figure 1).
Signals Involved in the Positive Regulation
of FGF23 by TGF-β, Calcineurin, and NFAT
TGF-β has been reported to regulate the extracellular matrix
by activating ROS, which increases calcium influx and activates
calcineurin (79–81). Using UMR-106 cells, TGF-β2 has been
described to enhance store-operated Ca2+ entry (SOCE)
and induce the stimulation of FGF23, an effect significantly
attenuated by both the inhibitor of TGF-β type I receptor activin
receptor-like kinases (ALK5, ALK4, and ALK7) SB431542 and
SOCE inhibitor 2-APB (82). Recent investigation has shown
that the synthesis of FGF23 in UMR-106 cells can be induced
by SOCE through Orai1 (83). In addition, the Ca2+ entry
activates the phosphatase calcineurin, which dephosphorylates
nuclear factor of activated T cells (NFAT) thereby stimulating
its transcriptional activity and targeting the Fgf23 gene. This
suggested that FGF23 may be positively regulated by calcineurin-
NFAT signaling (84). Further analyses confirmed that either
the inhibition of calcineurin using ciclosporin A (CsA) and
tacrolimus (FK-506) or the blocking of the interaction between
calcineurin and NFAT using the inhibitor INCA-6 reduced the
abundance of Fgf23 transcripts as well as FGF23 protein (84).
Additionally, lithium, a widely used drug for the treatment of
mood disorders and known to modify Ca2+ signaling, stimulated
the release of FGF23, partially through NF-κB dependent up-
regulation of Orai1 transcription and SOCE in UMR-106 cells
(85) (Figure 1).
Signals Involved in the Positive
Transcriptional Regulation of FGF23 by
Calcitriol
Early FGF23 physiological studies demonstrated that the
administration of 1,25D dose-dependently increased both serum
FGF23 as well as serum inorganic phosphorus in normal rats
(25). In wild type mice with normal renal function, injection of
calcitriol increased serum FGF23 levels 1-week post treatment
by 15-fold. Calcidiol (25-hydroxyvitamin D), although with a
lesser effect could also induce FGF23 in normal mice (86). In a
mouse model of adenine diet-induced CKD, a 5 weeks-regimen
induced a 40-fold increase of circulating FGF23. However, in the
background of a global deletion of Cyp27b1, the gene encoding
the enzyme vitamin D 1-α-hydroxylase involved in the formation
of calcitriol (1(OH)ase−/− mice), only a 2-fold circulating FGF23
was observed with this treatment, suggesting a contribution of
calcitriol to the increased FGF23. At the bone compartment level,
a specific deletion of Cyp27b1 in osteoblasts reduced FGF23
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induction in long bones from 58-fold in normal mice treated
with a 5-weeks adenine diet to a 10-fold induction, suggesting a
potential role of a local osteoblastic vitamin D conversion process
in the induction of bone FGF23. This attenuation of increased
FGF23 was independent of a potential reduction in PTH levels
since plasma PTH remained elevated in response to the adenine
diet-induced CKD in the mice with global deletion of Cyp27b1,
as well as those with osteoblast-specific deletion of Cyp27b1 (86)
(Figure 1).
NEGATIVE REGULATORS OF FGF23
Dentin Matrix Acidic Phosphoprotein 1 and
Phosphate-Regulating Gene With
Homologies to Endopeptidases on the X
Chromosome
The disease XLH is characterized by hypophosphatemia and
impaired mineralization caused by mutations of the phosphate-
regulating gene with homologies to endopeptidases on the X
chromosome (PHEX). Loss of PHEX leads to the overproduction
of FGF23 in osteocytes, causing hypophosphatemia with bone
mineralization impairment, and thus bone fragility. Similar
to XLH, recessive loss-of-function mutations in the dentin
matrix protein-1 (DMP1) gene, a member of small integrin-
binding ligand N-linked glycoprotein (SIBLING) proteins,
is responsible for a human phosphate wasting and impaired
bone mineralization disease termed autosomal recessive
hypophosphatemic rickets type 1 (ARHR1). It was shown that
a lack of DMP1 in both humans and mice markedly increased
FGF23 expression in bone (87).
To gain insight into the mechanisms by which PHEX
mutations upregulate FGF23 expression, studies have been
designed to investigate the local effects in bone from a mouse
model of XLH (Hyp mice) in a normal hormonal environment
in comparison to the function of wild type bone in the abnormal
metabolic environment of Hyp mice. Using a surgical procedure
to perform intramuscular bone cross-transplantations between
wild-type and Hyp mice, a study found that increased FGF23
expression in Hyp bone results from intrinsic PHEX deficiency
from bone, since FGF23 was increased in Hyp osteocytes before
and after explantation into WT mice but was not increased in
WT osteocytes after explantation into Hyp mice. This evidence
suggested that the mechanisms whereby PHEX mutations lead
to increased FGF23 expression in osteocytes is intrinsic to
bone (88).
Similar to the phenotype resulting from PHEX inactivation,
the inactivation of Dmp1 in mice resulted in equivalent intrinsic
bone mineralization defects associated with increased FGF23
expression in osteocytes (89–91). Using cortical bone isolated
from 12-days old WT, Hyp, Dmp1−/−, and Hyp/Dmp1−/−
mice to perform a genome-wide microarray analysis, the
phosphatidylinositol 3-kinase regulatory α subunit (PIK3R1)
and growth factor receptor-bound protein 2 (GRB2) pathways
were identified as potential common signaling controlled by
PHEX and DMP1 to regulate FGF23 promoter activity through
FGFs/FGFR in osteocytes (91, 92) (Figure 1). These findings
highlight that the activation of FGFRs which contribute to
FGF23 production in osteocytes may be independent from
the phosphate sensing pathways described above. Additionally,
recent in vivo and in vitro studies suggested a direct negative
regulation of DMP1 in FGF23 expression in osteocytes by
activating FAK-mediated MAPK signaling, thus coordinating the
extracellular environment of osteocytic lacunae as well as bone
metabolism (93) (Figure 1). The creation of the floxed-Fgf23
mouse has recently emerged as a critical tool to understand
FGF23 function in vivo (94). To this end, flox-Fgf23 mice were
mated to the global eIIa-cre which mimicked the phenotype
of the Fgf23-KO mouse. Fgf23 was also specifically deleted
from either the osteoblast lineage using the Col2.3 promoter to
drive Cre expression, or from late osteoblasts/osteocytes using
the Dmp1-Cre. This resulted in ∼50% reduction of iFGF23,
with compromised ability to respond to changes in phosphate
(94), demonstrating the specificity of osteoblast/osteocyte FGF23
production in response to metabolic changes.
Negative Regulation of FGF23 by Insulin
and Insulin-Like Growth Factor 1
Recent studies reported insulin and insulin-like growth factor
1 (IGF1) as negative regulators of FGF23 production in vitro
as well as in mice and humans (95). In vitro, insulin and
IGF1 down-regulated FGF23 production by inhibiting the
transcription factor forkhead box protein O1 (FOXO1) through
phosphoinositide 3-kinase (PI3K)/protein kinase B (PKB)/Akt
signaling in UMR-106 cells (95). In vivo, insulin deficiency
resulted in an increase of serum FGF23 concentrations in mice,
which was reversed by insulin administration. Interestingly, in
women subjects, an increase in plasma insulin levels following
an oral glucose administration correlated negatively with plasma
FGF23 concentrations (95) (Figure 1).
FGF23 CLEAVAGE: A PHYSIOLOGICAL
AND ENDOGENOUS MECHANISM TO
ATTENUATE FGF23 BIOACTIVITY
FGF23 is synthesized as a 251-amino acid protein, primarily
in osteocytes. The FGF23 signal peptide is represented by the
first N-terminal 24 aa. The cleavage of the signal peptide results
in a release of a mature peptide that can be secreted as the
bioactive hormone, referred to as “intact” FGF23 (“iFGF23”).
To control the bioactivity of iFGF23, the protein can be
cleaved at the subtilisin-like proprotein convertase (SPC) site
R176HTR179/S180AE (RXXR/SAE motif) generating at least
two fragments identified as an N-terminal fragment which
is structurally similar to other FGF family members and a
more unique C-terminal tail (21, 96). The proteolytic cleavage
of excess iFGF23 represents a critical secondary regulatory
mechanism to maintain stable serum iFGF23 and normal
serum phosphate. The absence of this proteolytic activity in
humans through the FGF23 gene mutations R176Q, R176W,
R179Q, and R179W are causative for autosomal dominant
hypophosphatemic rickets (ADHR), characterized by elevated
intact FGF23 and hypophosphatemia (21) (Figure 2). In mice
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carrying the ADHR point mutation R176Q-Fgf23, in response to
absolute iron deficiency using dietary intervention, the iFGF23
levels were elevated due to the stabilization of the bioactive
FGF23 (57). This elevated iFGF23 condition in response to
iron-deficient diet in ADHR mice caused similar phenotypes
as observed in ADHR/XLH patients, such as alterations in
genes controlling phosphate reabsorption and 1,25D production,
and a hypophosphatemic bone disease (57). These findings
suggested that iron status is a synergistic factor of the ADHR
phenotype, and that ADHR is a disease of gene-environment
interactions (57).
The cleavage of FGF23 is controlled by the serine
endoprotease furin, a subtilisin-like convertase, at the site
R179/S180 in response to several stimuli including PTH (78).
Previous investigations have shown that an iron deficient
state also promotes iFGF23 cleavage leading to increased
secretion of FGF23 fragments but normal iFGF23 in WT
mice (57, 58). In HeLa Cells, it was described that an iron
deficient state induces furin upregulation via the stabilization
of Hif1α (97), a similar mechanism which occurs in osteocytes.
Posttranslational modifications of iFGF23 can occur via the
O-glycosylation of Thr178 in the furin proprotein processing
motif RHT178R179, which stabilized FGF23 (98) (Figure 2).
This glycosylation process at Thr178 is controlled by the
enzymatic actions of N-acetylgalactosaminyltransferase
3 (GALNT3) which can be upregulated under high
phosphate conditions potentially via the control of FGFR1c
activation and the induction of the transcriptional activators
early growth response 1 (EGR1) and ETS variant 5
(ETV5) (28).
In a recent study, Thr178 was identified as a poor substrate
site with limited glycosylation acceptance, likely a protective
mechanism to prevent cellular resistances to FGF23 cleavage.
Interestingly, Thr178 glycosylation was shown to require a
previous glycosylation at Thr171 before generating a furin-
resistant and secreted stable iFGF23 (99) (Figure 2). These
new discoveries suggest that GALNT3 specificity for FGF23
and its ability to control circulating levels of bioactive
FGF23 is a control point achieved by FGF23 being a rather
poor substrate for this enzyme (99). In contrast to the O-
glycosylation induced by GALNT3 which stabilizes FGF23,
the phosphorylation at position S180 by the kinase FAM20C
inhibited O-glycosylation of FGF23, thus promoting FGF23
cleavage (98) (Figure 2). Indeed, recessive inactivating mutations
in human FAM20C cause ARHR type 3 (ARHR3; Raines
syndrome), consistent with its role as an FGF23 de-stabilizer
(100, 101).
Besides furin which is thought to cleave FGF23 mainly
intracellularly, the extracellular proteases of the plasminogen
activation system, tissue-type PA (tPA), and urokinase-type PA
(uPA), as well as plasmin may also display proteolytic activity
on FGF23 protein at the RXXR motif (R176), with potential
additional cleavages at arginine residues R114, R140, R143, R160,
R196, and R228 (102). Of note, Klotho knock out mice as
well as mice with acute kidney injury, which both exhibit
elevated levels of intact FGF23, also display elevated plasminogen
activator inhibitor-1 (103, 104). Thus, the proteolysis of FGF23
by tPA, uPA, and plasmin may potentially regulate the levels
of active FGF23 thus in part, controlling phosphate and
mineral homeostasis.
These collective studies demonstrated that FGF23 protein
cleavage is a dynamic process which can be adjusted after
production at the cell level with phosphorylation and
glycosylation dictating the levels of bioactive FGF23 depending
upon the osteocyte cell state. Certainly, future studies are needed
to understand the regulation of GALNT3, furin, FAM20C, and
potentially the enzymes of the plasminogen activation system in
the coordinated control of FGF23 production and bioactivity.
FGF23 RENAL SIGNAL TRANSDUCTION
In contrast to paracrine FGFs, such as FGF1 and FGF2, endocrine
FGFs such as FGF23 lack the heparin-binding domain in
their C-terminus, which enables escape from the osteocyte cell
matrix after secretion and their actions on distant target organs
including kidney (14, 105). FGF23 acts primarily on kidney to
promote phosphaturia and parallel reductions in 1,25D (14, 34).
The phosphaturic activity of FGF23 is critical in CKD, preventing
and delaying hyperphosphatemia and vascular calcifications
as FGF23 progressively rises with the loss of renal function
(106). In a study among patients undergoing hemodialysis,
high serum phosphate levels across a quartile of patients (>5.5
mg/dl) was associated with a 20% increase in the multivariable
adjusted risk of death, as compared with normal levels (3.5–
4.5 mg/dl) (107). These findings underscore the importance
of controlling circulating phosphate in kidney disease patients.
During CKD, as kidney function decreases with a progressive
decrease of glomerular filtration rate (GFR), the kidney loses
functioning nephrons decreasing the overall excretion capability
of the kidney. The dramatic rise of FGF23 during CKD is
likely to attempt to boost the excretory capacity of the existing
nephrons to maintain normal serum phosphate levels. This is
likely the primary reason why early stage CKD patients exhibit
normal serum phosphate over much of the disease course [for
review (108)].
FGF23 actions are likely mediated by FGF receptors FGFR1c,
FGFR3c, and FGFR4 and the co-receptor Klotho, a single-pass
transmembrane protein highly expressed in kidney (109–113).
FGF23 binds to FGFR1c and the interaction between these
two proteins with the co-receptor Klotho (which dramatically
increases the binding affinity of the complex FGF23-FGFR-
Klotho) triggers potent FGF23 signaling and activity (114). In
kidney, FGF23 signaling on the basolateral side of proximal
nephron cells causes the internalization of the sodium-dependent
phosphate co-transporters NPT2A and NPT2C from the apical
surface. These actions decrease phosphate reabsorption processes
from the kidney (115) (Figure 3). A global genetic deletion of
FGF23 in mice resulted in severe hyperphosphatemia, due to the
absence of the FGF23-mediated phosphaturia mechanism (116).
In addition, FGF23 signaling regulates vitamin Dmetabolism via
the modulation of the vitamin D metabolic enzymes expression
as well as regulating calcium and sodium reabsorption processes
(Figure 3).
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FIGURE 2 | Schematic representation of the possible fates of FGF23. In (A), the amino acid sequence of human FGF23 is shown with its signal peptide, FGFR
binding region, the RXXR motif/cleavage sequence, and the Klotho binding region. In (B), the possible fates of mature FGF23 after the loss of its signal peptide
sequence is displayed. The O-glycosylation of T178, a process controlled by N-acetylgalactosaminyltransferase 3 (GALNT3) and which requires a precedent
glycosylation at T171, stabilizes and prevents FGF23 cleavage. This process may also be stimulated by increased levels of phosphate which induces GALNT3 and the
glycosylation. Genetic modifications such as autosomal dominant hypophosphataemic rickets (ADHR) mutations R176Q, R176W, R179Q, and R179W stabilize
FGF23 and counteract its natural cleavage. Phosphorylation at position S180 by FAM20C increases FGF23 cleavage controlled by the furin/subtilisin-like proprotein
convertase. FGF23 proteolysis may occur at R176 by extracellular proteases of the plasminogen activation system, tissue-type PA (tPA), urokinase-type PA (uPA), and
plasmin. This proteolysis could potentially occur at the RXXR motif (R176) as well as at different arginine residue sites at R115, R140, R143, R160, R196, and R228.
Unbiased Approaches to Understanding
FGF23 Function in Kidney
Unbiased studies using large-scale microarray and gene
expression approaches from FGF23 transgenic (FGF23 Tg)
mice and WT littermates have identified several renal genes
associated with increased FGF23. Particularly, genes involved
in the phosphate reabsorption process such as Npt2a, Pdzk1 (a
scaffolding protein known to interact with Npt2a) and Klotho,
the co-receptor for FGF23 were among the genes which showed
significantly decreased expression (117). The angiotensin I
converting enzyme 2 (Ace2), known to decrease Angiotensin
II with potential disruption of the renin-angiotensin system
balance (118) was also decreased in FGF23 Tg kidney (117).
It was later hypothesized that FGF23 induced the activation
of FGFR1, leading to Ace2 reduction, causing hypertension
(119). Other genes such as Atp1a2, which has been described to
interact with Klotho and regulate calcium metabolism (120), was
2.5-fold- upregulated (117) and lipocalin 2, a neutrophil-derived
marker previously described to be involved in CKD progression
in mice and humans (121), was also modestly induced (117).
Other approaches using an acute 1-h FGF23 injection revealed
that the MAPK related transcription factor Egr1 is typically the
most up-regulated gene in microarray datasets testing FGF23
bioactivity. It was also determined that EGR1 binding near genes
encoding Npt2a, Npt2c, as well as scaffold proteins (NHERF1-
3, EZR and GABARAP), and trafficking proteins (megalin and
vacuolar ATPase), known to putatively mediate NPT2A protein
internalization and degradation, were increased after FGF23
injection. Collectively, these results suggested a coordinated
regulation of renal Pi transport genes through EGR1 (122).
EGR1: An FGF23 Biomarker and Beyond
Asmentioned above, it has been well-studied that FGF23 delivery
induces EGR1, a transcription factor and downstream marker of
MAPK signaling, in mice and cells (112, 123). It was shown in
the Hyp mouse that MAPK/ERK1/2 signaling is activated in the
kidney and this pathway induction drives EGR1 (112, 123). Other
studies revealed that an inhibition of ERK1/2 signaling using
a selective MEK inhibitor, PD0325901, was associated with a
reduction of renal Egr1 upregulation induced by a Phex deletion.
This led to improvement in the hypophosphatemia associated
with decreased NPT2a protein expression, correction of 1,25D
and calcium deficiency, with a reduction of cortical porosity
(124, 125).
To further understand the contribution of Egr1 on FGF23-
dependent regulation of renal Pi and vitamin D metabolism,
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FIGURE 3 | FGF23 signaling in the kidney. In kidney proximal tubules, circulating FGF23 binds to FGFR1-Klotho complexes at the basolateral membrane, and
activates the MAPK signaling cascade involving ERK1/2. This signaling leads to the internalization and degradation of NPT2A/C and the decrease of urinary phosphate
reabsorption promoting phosphate wasting. In the proximal tubule, FGF23 signaling induces downstream mechanisms which suppress the transcription of the vitamin
D 1α-hydroxylase (CYP27B1) and increases the transcription of the vitamin D 24-hydroxylase (CYP24A1); both events work in concert to limit the conversion of 25D to
1,25D as well as degrading 1,25D into inactive metabolites. In the kidney distal tubule, circulating FGF23 binds to the FGFR-Klotho receptor complex at the basolateral
membrane, and activates the MAPK/pERK/EGR1 pathway as well as cascade signaling for ERK1/2, SGK1, and the WNK4 complex via their phosphorylation.
Activation of WNK signaling increases the expression of TRPV5 and NCC at the apical membrane promoting the reabsorption of calcium and sodium, respectively.
the Egr1 knockout mouse (Egr1−/−) has been studied with
interesting findings. Reports showed that the effect of FGF23-
induced decreases in renal Npt2a and Npt2c proteins is
completely abrogated in Egr1−/− mice (122). To potentially
attenuate Egr1 activity, FGF23 also upregulates two isoforms
of Nab2 which are known to be corepressors of Egr1
(126); however whether this is a direct or an indirect
mechanism through Egr1, which is known to induce Nab2
thus establishing a negative feedback loop (127), remains to
be investigated.
Physiological Role of Renal FGF23
Receptors
Four FGFR isoforms (FGFR 1-4) have been described in
mammals and an alternative splicing of these isoforms can
generate seven major FGFR proteins (FGFRs 1b, 1c, 2b, 2c,
3b, 3c, and 4) (105). FGFR1, FGFR3, and FGFR4 are the most
expressed FGFRs in the mouse kidney with potential functional
roles in mineral homeostasis (128–130). In mice, a deletion
of Fgfr1, Fgfr2, Fgfr3, and Fgfr4 from renal proximal tubules
induces hyperphosphatemia, hypercalcemia, hypervitaminosis
with elevated FGF23 (128). Other studies using mice with
a specific deletion of FGFR1 in distal tubule segments have
suggested that FGF23 activates FGFR1/alpha-Klotho complexes
in the distal tubule leading to an increase of sodium-chloride
symporter (NCC)-dependent sodium (Na) reabsorption, a
decrease of Ace2 and renal KIotho, leading to increased blood
pressure and hypertension (119). Further, activation of FGFR1
using pharmacologic intervention normalized blood pressure in
Hyp mice, a mouse model of elevated FGF23 (119). Although
the roles of FGFR3 and FGFR4 in kidney are not completely
understood, in vivo studies proposed that FGFR3 and FGFR4
may contribute by acting in concert with FGFR1 to mediate
FGF23 effects in kidney. Although their roles may be less
substantial at the physiological level, under conditions of high
circulating FGF23 in Hyp mice, the deletion of FGFR3 leads
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to a feedback stimulation of Fgf23 mRNA expression in bone
(129, 131), suggesting complex kidney-bone crosstalk.
The co-receptor KL is required for high-affinity FGF23
activity in the kidney. Whole-nephron deletion of Klotho
in mice results in renal FGF23 resistance, characterized by
hypervitaminosis D, hyperphosphatemia, and other phenotypes
that may resemble premature aging (39, 132). However, provision
of a low phosphate diet to KL-null mice reversed the severe
phenotypes, showing that the majority of KL-null phenotypes
are due to extreme phosphate imbalances (133, 134). Klotho is
highly expressed in the distal tubule segments of the nephron
in comparison to its relatively modest expression in proximal
tubules (123) although the phosphate reabsorption occurs
primarily in the proximal tubules due to an abundant expression
of the sodium phosphate transporters Npt2a and Npt2c (135–
137). To delineate and identify the main effector sites of FGF23
actions in kidney, recent elegant studies have been performed
using mouse models with nephron segment-specific deletion
of Klotho in concert with a full characterization of mineral
metabolism of these mice (138, 139). Olauson et al. generated a
mouse model with deletion of Klotho in distal tubular segments
(Ksp-KL2/2) which was characterized as fertile with a normal
gross phenotype despite a disrupted mineral metabolism. These
phenotypes were in contrast to Klotho-null mice which are not
fertile in addition to undergoing premature death and severe
vascular calcifications (138). By using immunohistochemistry
analysis, investigators showed that partial deletion of Klotho
in distal tubule resulted in hyperphosphatemia with elevated
plasma FGF23 and increased Npt2a protein expression in the
proximal tubule apical membrane (138). In other studies where
Klotho was conditionally deleted from renal proximal tubule,
the mineral metabolism phenotype was variable depending
upon the strategies used to perform specific Klotho deletion.
Indeed, in the studies of Ide et al., only a mild phenotype on
mineral metabolism with a decrease of urinary phosphate was
observed when Klotho was deleted from proximal tubules
using three different proximal tubule specific Cre transgenic
mice: Kap-Cre (kidney androgen-regulated protein), Slc34a1-
Cre (sodium phosphate cotransporter-2a1) or Pepck-Cre
(phosphoenolpyruvate carboxykinase) (139). The latter, harbors
elevated serum iFGF23 and a slight increase in Npt2a protein
(139). In contrast, other studies using an inducible promoter-
Cre, Ndrg1-Cre, to delete Klotho from proximal tubules revealed
a more pronounced effect on mineral metabolism with markedly
elevated iFGF23 and hyperphosphatemia (128). The phenotypic
differences across these mouse models could be explained by the
variability in Cre-mediated recombination efficiency, which can
be factored by the cell-type specificity of Cre expression, the Cre
expression efficiency in specific cell types, and the recombination
feasibility from different genetic modification strategies.
It was later shown that FGF23 signaling can cross-talk with
PTH signaling to control mineral metabolism. A deletion of
both PTH1R and Klotho from the kidney proximal tubule
(PT-PTH1R/KL−/− mice) led to a severe disturbance of
mineral metabolism including hyperphosphatemia at baseline
and increased circulating phosphate in response to high
phosphate diet (140). The hyperphosphatemia observed in PT-
PTH1RKL−/− mice was associated with elevated circulating
FGF23, PTH, decreased circulating 1,25D and increased Npt2a
(140). These new data underscore that FGF23 and PTH
signaling pathways can interact in kidney thus coordinating renal
phosphate handling in the proximal tubule (140, 141).
Using animal models, studies confirmed over recent years
that FGF23 is a negative regulator of 1,25D production. Indeed,
FGF23 potently inhibits the expression of the 25(OH)D-1α-
hydroxylase CYP27B1 in the renal proximal tubule while
stimulating in contrario the expression of the vitamin D catabolic
enzyme CYP24A1 at the mRNA level (23, 142–144). Mice with
global deletion of the Fgf23 gene displayed elevations in serum
1,25D by 2-4 fold (144). Since FGF23 acts as a requisite partner
with its co-receptor Klotho to control mineral metabolism,
Klotho ablation in mice resulted in a strikingly similar phenotype
to the Fgf23-null mice, including increased serum levels of
1,25D associated with increased renal Cyp27b1 expression
(39, 145). Interestingly, the premature aging-like phenotype
of Fgf23−/− and Klotho−/− mice can be completely rescued
using a genetic approach to ablate 1,25D synthesis through
the generation of double mutant Fgf23−/−/1α(OH)ase−/− and
Klotho−/−/1α(OH)ase−/− mice (146, 147). These data suggested
that increased vitamin D played a major role in the abnormal
mineral ion metabolism and soft-tissue anomalies observed in
Fgf23−/− and Klotho−/− mice. Although Klotho deletion results
in hypervitaminosis, and the kidney is the predominant organ
expressing Klotho, studies using targeted deletion of Klotho
in the proximal or distal tubule segment of the nephron have
shown an overall modest effects on circulating vitamin D levels
(138, 139), likely due to endocrine compensation.
It has also been described that the deletion of vitamin D
receptor (VDR) in Fgf23−/− and Klotho−/− mice rescued these
mice from an early lethality phenotype due to the absence of
vitamin D signaling causing reduced phosphate absorption (148,
149). Therefore, Fgf23−/−/VDR1/1 and Kl−/−/VDR1/1 double
mutant mice can be used to examine the roles of FGF23 and
Klotho at older ages by keeping these mice on a rescue diet rich
in calcium, phosphorus, and lactose (150, 151) with the goal of
preventing hypocalcemia and severe hyperparathyroidism due to
the non-functioning VDR status.
Study of the Fgf23−/−/VDR1/1 and Kl−/−/VDR1/1 mice
showed that the deletion of Fgf23 or Klotho leads to a decrease
in the membrane abundance of NCC (the sodium chloride
cotransporter) in the kidney distal tubule and subsequently to
decreased Na+ reabsorption (152). In contrast, treatment of
WT mice with FGF23 over 5 days upregulated distal tubular
NCC resulting in increased Na+ reabsorption and increased
blood Na+ concentrations (152). Using Hyp mice with elevated
FGF23, studies have also shown that these mice have increased
distal tubular Na+ uptake and membrane abundance of NCC
(152). It was explored whether the effects of FGF23 on NCC
expression in kidney may potentially drive physiological changes
including hypertension and heart hypertrophy in a αKlotho-
dependent manner. The inhibition of NCC using chlorothiazide
abrogated FGF23-induced heart hypertrophy suggesting that
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FGF23 may act as a potential regulator of renal Na+ reabsorption
with downstream consequences, although patients with FGF23-
related gain or loss of function mutations primarily show
more severe defects in phosphate metabolism. Another mineral
that may be regulated by FGF23 in distal tubule is calcium
(153). In this regard, studies have shown that renal calcium
reabsorption and renal membrane abundance of TRPV5 are
reduced in Fgf23−/−/VDR1/1 and Kl−/−/VDR1/1 double
mutant mice (153).
Renal FGF23 Signal Transduction
Although FGFR1c, 3c, and 4 are ubiquitously expressed, Klotho
expression is predominantly expressed in specific tissues such as
kidney renal tubules, parathyroid gland, and choroid plexus of
brain, suggesting that these organs are the physiological targets
for FGF23-mediated endocrine actions (39, 154, 155). FGF23
preferentially binds to FGFR1c and Klotho, and this complex
initiates FGFR1c signal transduction via the cytoplasmic adaptor
FRS2α (156), which activates the FRS2α/Ras/MAPK pathway
(157) (Figure 3). In vitro studies using human embryonic kidney
cells (HEK293), which endogenously express FGFRs but not
Klotho (158), showed that the presence of soluble Klotho (sKL) or
membrane-bound Klotho (mKL) is required for FGF23-induced
MAPK activity, which was assessed by pERK1/2 induction and
EGR1 mRNA expression (157, 159). Although initial studies
suggested that mKL and sKL share a common function of
mediating FGF23-induced FRS2α/Ras/MAPK signaling, recent
findings suggested that FGF23 responses were quantitatively
different depending on mKL or sKL availability (159). In vivo
studies, potentially using genetic targeting to isolate the biological
effects of mKL from sKL will be required to deepen our
understanding of these interactions.
In the absence of Klotho, in HEK293 cells, FGF23 alone can
activate pPLCγ and pAKT, and these activities are completely
neutralized by the presence of Klotho (159, 160). These studies
further suggested that FGF23 preferentially induced FGFR1c
signaling via Klotho. However, in the absence of Klotho,
high concentrations of FGF23 can activate FGFR4 (157). The
activation of FGFR4 was shown to induce PLCγ-catalyzed
production of diacylglycerol and inositol 1,4,5-triphosphate
that increased cytoplasmic calcium levels, thereby activating
several calcium-sensing signal mediators, including the protein
phosphatase calcineurin (157). The activation of calcineurin
dephosphorylates the transcription factor NFAT, which permits
its translocation into the nucleus to modulate the expression of
specific target genes (161). This FGFR4-mediated effect may play
a key role in cardiac hypertrophy through FGFR4 during highly
elevated FGF23 in CKD (157, 162).
The phosphaturic action of FGF23 in kidney proximal
tubule and actions in the distal tubule may occur primarily
through FGFR1c, the main “phosphaturic” FGFR expressed in
both segments and colocalized with Klotho (123, 129). A C-
terminal FGF23 peptide antagonist has been developed recently
to block FGF23 signaling by inhibiting tyrosine phosphorylation
of FRS2α and downstream activation of the MAPK cascades
(34). Studies in Hyp mice using this novel peptide confirmed
that the inhibition of FGF23 signaling in kidney upregulates
the expression of the sodium-phosphate cotransporters Npt2a
and Npt2c, coupled with the alleviation of the observed
hypophosphatemia (34). In a mouse model of CKD, this FGF23
antagonist peptide has been shown to rescue the prevailing
anemia (163).
Beside the effects of FGF23 on phosphate homeostasis,
FGF23 signaling has been described to promote renal calcium
reabsorption through the TRPV5 channel. Indeed, the apical
membrane abundance of TRPV5 in renal distal tubules could be
regulated by the binding of FGF23 to FGFR-Klotho complexes
which activated a signaling pathway implicating ERK1/2, SGK1,
and WNK4. This signaling pathway led to the increase of
intracellular transport of fully glycosylated TRPV5 from the
Golgi apparatus to the apical plasma membrane, thus decreasing
the renal loss of calcium (153). In distal convoluted tubule, the
ERK1/2-SGK1-WNK4 signaling pathway leads to WNK4 serine
phosphorylation at residue 71 and kinase activation. FGF23
promoted the physical interaction between NCC and WNK4,
increasing NCC membrane abundance, and would promote
sodium reabsorption (152). Additional studies of the actions of
FGF23 and Klotho specifically within the kidney distal tubule are
required to determine the full extent of kidney FGF23 bioactivity.
CONCLUSION
The hormone FGF23 is mainly produced by osteocytes
with the ability to target distant organs such as kidney. In
late osteoblasts and osteocytes, FGF23 can be upregulated
by elevated phosphate, anemia, inflammation, PTH and
1,25D; and downregulated by hypophosphatemia, insulin,
and insulin-like growth factor 1. Although not covered
here, studies have shown that FGF23 can be produced
at lower levels by other cells such as immune cells, bone
marrow erythroid cells and other tissues such as liver in
response to diverse stimuli (106, 164). The posttranslational
modifications of FGF23 protein via O-glycosylation and
phosphorylation controls the proteolytic cleavage of
mature FGF23 protein which dictates biologically active
FGF23 concentrations.
The binding of FGF23 to FGFR1-Klotho complexes in
the kidney has been shown to induce a signaling cascade
through MAPK which controls mineral metabolism. The
signals induced by FGF23 in kidney downregulate the
expression of Npt2a/c leading to decreased phosphate
reabsorption in proximal tubules, and upregulation of
TPRV5 and NCC, potentially promoting calcium and
sodium reabsorption, respectively, in the distal tubule.
Alterations of FGF23 expression in osteocytes, FGF23
processing, and FGF23 activity cause severe endocrine
pathologies resulting in rare and common diseases. Thus,
further understanding the mechanisms controlling FGF23
production in osteocytes and bioactivity in kidney will lead to
improved patient outcomes.
In summary, although much is known regarding FGF23
regulation and actions, gaps in our knowledge exist. These
include the potential contributions of bone cells such as
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osteoblasts and osteoclasts in the regulation of osteocytic FGF23,
and it remains unclear whether aged osteocytes (mature cells
and deeply embedded in the mineralized bone matrix) are
more effective in terms of upregulating FGF23 in response
to physiological and pathological changes vs. early osteocytes.
Finally, whether FGF23 can target other cell-types in the kidney
beyond its defined actions on proximal and distal tubules
remains unknown, thus future investigation could examine the
effects of FGF23 on renal immune cells such as macrophages
and regulatory T cells, critical for the control of renal
inflammation and kidney remodeling during acute kidney injury
and CKD.
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